Academic Journal
Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015
| العنوان: | Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015 |
|---|---|
| المؤلفون: | Olesen, Tina Bech, Andersen, Ina Trolle, Ording, Anne Gulbech, Ehrenstein, Vera, Seesaghur, Anouchka, Helleberg, Carsten, Silkjær, Trine, Hernandez, Rohini K., Niepel, Daniela, Abildgaard, Niels |
| المصدر: | Olesen , T B , Andersen , I T , Ording , A G , Ehrenstein , V , Seesaghur , A , Helleberg , C , Silkjær , T , Hernandez , R K , Niepel , D & Abildgaard , N 2021 , ' Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015 ' , Supportive Care in Cancer , vol. 29 , no. 8 , pp. 4501-4511 . https://doi.org/10.1007/s00520-020-05934-8 |
| سنة النشر: | 2021 |
| المجموعة: | Aarhus University: Research |
| مصطلحات موضوعية: | Bisphosphonates, Epidemiology, Multiple myeloma, Severity of Illness Index, Humans, Middle Aged, Male, Bone Density Conservation Agents/therapeutic use, Disease Progression, Diphosphonates/therapeutic use, Denmark, Female, Registries, Aged, Kidney Diseases/chemically induced, Multiple Myeloma/drug therapy, Bone Neoplasms/drug therapy, Cohort Studies |
| الوصف: | Purpose: To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark. Methods: Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications. Results: Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphosphonates. During a median follow-up of 27.6 (quartiles, 10.6–52.5) months, disease progression post-first-line treatment was recorded in 1546 patients, of whom 1065 (68.9%) were treated with bisphosphonates. Altogether, 80.9% of patients with and 37.6% of patients without myeloma bone disease were treated with bisphosphonates at first line and 73.0% and 42.7%, respectively, at progression/second line. Moreover, the proportion of patients treated with bisphosphonates decreased with increasing severity of renal impairment at first and at progression/second-line treatment. Conclusion: The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1007/s00520-020-05934-8 |
| الاتاحة: | https://pure.au.dk/portal/da/publications/use-of-bisphosphonates-in-multiple-myeloma-patients-in-denmark-20052015(c34dcdb2-de24-4674-8dce-32fbd2f56e2d).html https://doi.org/10.1007/s00520-020-05934-8 http://www.scopus.com/inward/record.url?scp=85100136741&partnerID=8YFLogxK |
| Rights: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.8E37F73A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00520-020-05934-8 |
|---|